Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

General Information

Offices

Utrecht, NLD
Padualaan 8 (postvak 133)
Utrecht, 3584 CH, NLD

People

Funding

Tags

Merus

Merus B.V., a biomedical company, engages in the discovery and development of antibody-based biopharmaceuticals. It develops Oligoclonics technology that offers a class of human antibodies, called Oligoclonics. Oligoclonics is a concept whereby a mixture of various human therapeutic antibodies, directed to a common antigen are produced from a single cell clone. The company was founded in 2003 and is based in Driebergen, the Netherlands.

Recent Milestones

Videos

Screenshots

Merus screenshot
Above: Home Page
Uploaded: 2/1/10

Sources

  1. Merus closes EUR 21.7 million Series B financing and enters option agreement with the Novartis Option Fund (merus.nl) [edit]
  2. Merus Raises €31M in Series B Financing (finsmes.com) [edit]
Edit This Page
Last Edited 12/11/13

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize »

Techmeme Posts Techmeme Logo Small Picture

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy